StreetInsider.com News Articles

TG Therapeutics publishes five-year Briumvi comparison study

Mon, 12 Oct 2026 07:30:53 -0400

TG Therapeutics, Inc. (NASDAQ: TGTX) announced the publication of a five-year matching-adjusted indirect comparison (MAIC) analyzing outcomes of its multiple sclerosis drug Briumvi (ublituximab-xiiy) against ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS).

The study, published in Multiple Sclerosis and Related Disorders, used individual patient data from 545 participants in the Phase 3 ULTIMATE I and II trials and compared outcomes against published aggregate data from the Phase 3 OPERA I/II trials of ocrelizumab and ASCLEPIOS I/II trials of ofatumumab.

According to the analysis, Briumvi was associated with a 44% lower relative hazard of 24-week confirmed disability progression versus ocrelizumab

TG Therapeutics publishes five-year Briumvi comparison study

Mon, 12 Oct 2026 07:30:53 -0400

According to the analysis, Briumvi was associated with a 44% lower relative hazard of 24-week confirmed disability progression versus ocrelizumab

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

Mon, 12 Oct 2026 07:30:00 -0400

BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab

NEW YORK--(BUSINESS WIRE)-- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). For the analysis, individual patient data from the Phase 3 ULTIMATE I/II pivotal trials for BRIUMVI were reweighted to match published baseline characteristics from the pivotal studies for

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

Mon, 12 Oct 2026 07:30:00 -0400

BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

Thu, 08 Oct 2026 07:30:00 -0400

Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic “off-the-shelf” CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis

Additional presentations include Phase 3 ENHANCE data supporting the investigational BRIUMVI single dose initiation schedule, full Phase I subcutaneous BRIUMVI results, seven-year clinical outcomes and growing real-world evidence

NEW YORK--(BUSINESS WIRE)-- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

Thu, 08 Oct 2026 07:30:00 -0400

Form 4 TG THERAPEUTICS, INC. For: Sep 10 Filed by: Charney Laurence N

Mon, 14 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260914/27059169.html

Form 144 TG THERAPEUTICS, INC. Filed by: Charney Laurence N

Thu, 10 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260910/27049137.html

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market